50534-23-1

Basic information

• Product Name: 4-ACETAMIDO-1-BENZYLPIPERIDINE
• Synonyms: N-(1-Benzylpiperidin-4-yl)acetamide;N-Acetyl-1-benzyl-4-aminopiperidine;4-ACETAMIDO-1-BENZYLPIPERIDINE
• CAS NO: 50534-23-1
• Molecular Formula: C₁₄H₂₀N₂O
• Molecular Weight: 232.32
• Mol File: 50534-23-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 140 °C
• Boiling Point: 401.3 °C at 760 mmHg
• Flash Point: 196.5 °C
• Appearance: /
• Density: 1.08 g/cm³
• Vapor Pressure: 1.19E-06mmHg at 25°C
• Refractive Index: 1.559
• Solubility: soluble in Methanol
• PKA: 15.92±0.20(Predicted)
• CAS DataBase Reference: 4-ACETAMIDO-1-BENZYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ACETAMIDO-1-BENZYLPIPERIDINE(50534-23-1)
• EPA Substance Registry System: 4-ACETAMIDO-1-BENZYLPIPERIDINE(50534-23-1)

Safety Data

• Hazardous Substances Data: 50534-23-1(Hazardous Substances Data)

Usage

General Description

4-Acetamido-1-benzylpiperidine is a chemical compound that belongs to the class of benzylpiperidine derivatives. It is a combination of 4-acetamidophenol and 1-benzylpiperidine, and is commonly used in the field of medicinal chemistry. 4-Acetamido-1-benzylpiperidine has been studied for its potential medical applications, including its analgesic and anesthetic properties. Additionally, it has been investigated for its potential as a drug precursor. The specific properties and applications of 4-Acetamido-1-benzylpiperidine make it a subject of ongoing research in the pharmaceutical and medical fields.

InChI:InChI=1/C14H20N2O/c1-12(17)15-14-7-9-16(10-8-14)11-13-5-3-2-4-6-13/h2-6,14H,7-11H2,1H3,(H,15,17)

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 50534-24-2 1-phenylmethyl-4-ethylaminopiperidine 
• 5810-56-0 4-(acetylamino)piperidine 
• 181579-49-7 N²-(1-Benzyl-piperidin-4-yl)-N²-ethyl-N³-isopropylidene-pyridine-2,3-diamine 
• 179558-09-9 1-benzyl-4-[N-ethyl-N-(3-amino-2-pyridinyl)amino]piperidine 
• 179558-10-2 1-Benzyl-4-[N-ethyl-N-(3-(ethylamino)-2-pyridinyl)amino]piperidine 
• 179557-99-4 1-benzyl-4-[N-ethyl-N-(6-fluoro-3-(amino)-2-pyridinyl)amino]piperidine 
• 179558-70-4 1-benzyl-4-[N-ethyl-N-(3-amino-6-chloro-2-pyridinyl)amino]piperidine 
• 179557-94-9 1-Benzyl-4-[N-ethyl-N-(3-propylamino-2-pyridinyl)amino]piperidine 
• 179557-43-8 1-benzyl-4-[N-ethyl-N-(3-(1-methylethylamino)-2-pyridinyl)amino]piperidine 
• 179558-08-8 1-benzyl-4-[N-ethyl-N-(3-nitro-2-pyridinyl)amino]piperidine 
• 179558-00-0 1-Benzyl-4-[N-ethyl-N-(6-fluoro-3-(isopropylamino)-2-pyridinyl)amino]piperidine 
• 179557-48-3 1-benzyl-4-[N-ethyl-N-(3-(1,1-dimethylethylamino)-2-pyridinyl)amino]piperidine 
• 181579-50-0 N²-(1-Benzyl-piperidin-4-yl)-N²-ethyl-6-fluoro-N³-isopropylidene-pyridine-2,3-diamine 
• 179557-98-3 1-Benzyl-4-[N-ethyl-N-(6-fluoro-3-(nitro)-2-pyridinyl)amino]piperidine 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Route selection and process development of a multikilogram route to the inhaled A2a agonist UK-432,097

This article describes the selection, process development, and scale-up of a synthetic route to a complex nucleoside analogue, the A2a agonist UK-432,097 (1), that culminated in the manufacture of over 25 kg of the API. The key steps in the process were (1) a stereoselective glycosidation reaction; (2) a scalable bleach-TEMPO oxidation; and (3) an unusual elevated temperature crystallization process for the final API. The problems that were encountered with the scale-up of the route together with how they were overcome are also presented.

TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY

The present invention provides compounds of formula (I) Wherein R1 , R2, R3 , R4 , Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.